Pharmacuetical Companies Eye Orphan Drugs As New Revenue Source

The New York Times: Making 'Every Patient Counts' A Business Imperative
Drug companies are fond of saying that every patient counts, but in the world of orphan diseases, entire business plans are built around the idea. ... Development of these drugs is increasingly attractive to pharmaceutical companies, which are searching for new sources of revenue as sales of more traditional, mass-market drugs have been lost to generic competition. The orphan drug market was worth more than $50 billion in 2011 and turns out blockbusters at the same rate as the broader industry, according to a recent Thomson Reuters analysis (Thomas, 1/30).

This is part of Kaiser Health News' Daily Report - a summary of health policy coverage from more than 300 news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Report here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.